ORLANDO — Qlosi demonstrated consistent pupil size reduction and increasing rates of near visual acuity in patients with presbyopia over 8 days, according to a study.
Mitchell A. Jackson, MD, of Jacksoneye in Lake Villa, Illinois, presented data from the phase 3 NEAR trials at the American Academy of Ophthalmology meeting.
The two identically designed, parallel-group studies evaluated Qlosi (pilocarpine hydrochloride ophthalmic solution 0.4%, Orasis Pharmaceuticals) in 613 patients aged 45 to 64 years with distance corrected near visual acuity of 20/50 to 20/160 in the study eye with dark